> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Accepts CSL Behring sBLA for New Indication
- URL: https://www.fdaweb.com/fda-accepts-csl-behring-sbla-for-new-indication/
- Published: 2017-02-14T12:00:00.000Z
- Updated: 2026-09-14T22:06:20.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5137973

FDA has accepted for review a CSL Behring clinical efficacy supplement on its BLA for to [Privigen](http://www.privigen.com/?ref=fdaweb.com) \[immune globulin intravenous (human), 10% liquid\], its intravenous immunoglobulin. The supplement seeks to obtain approval for a new indication — treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare and progressing disease that may cause permanent nerve damage. If approved, this would be the third approved indication for Privigen after primary immunodeficiency and immune thrombocytopenic purpura.

  
The supplement is based on clinical trial data from CSL Behring's PRIMA and PATH studies, both focused on using immunoglobulin therapy for treating CIDP. Results suggest that Privigen may help decrease weakness and loss of motor function in people with CIDP, the company says.